Handelsavisen
prelaunch
Companies Healthcare ENOV.K
EN
ENOV.K NYSE Health Care Equipment & Supplies

Enovis Corp

$28,25
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
1,6B USD
P/E
EV / Rev
1,2x
Div yield
Op margin
-47,1 %
ROE
-76,3 %
Net margin
-49,9 %
Debt / equity
0,85
Beta
52w range
Volume
Day range
Prev close
$28,25
Open
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

Enovis Corp operates in the Health Care Equipment & Supplies industry, generating revenue through the sale of medical devices and related products.

Business. Enovis Corp (ENOV.K) is a health care equipment and supplies company that operates within the medical device industry. The firm is headquartered in the United States and is primarily listed on the New York Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.

Classification85 %
SectorHealth Care
Industry groupHealth Care Equipment & Supplies
Generated · model-assisted
Sell-side consensus
BUY12 analysts
11 buy1 hold0 sell
Avg 12m price target41,09

Analyst recommendations

12 analysts · consensus Buy
Buy11
Hold1
Sell0
12-month price target
41,09
Consensus of sell-side coverage.
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
12 analysts · indicative
Ownership
American Century Investment Management, Inc.
largest disclosed fund holder
Profitability
-76,3 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning ENOV.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to ENOV.K. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    Briefing · model-assisted

    Enovis Corp (ENOV.K) has recorded a notable addition to its shareholder base, marking the first analysis for this ticker with no prior basis for delta computation. This initial snapshot establishes the baseline for tracking future ownership shifts and market interest in the company. The specific change involves a new holder, identified by investor ID 929, who acquired 200,000 shares as of March 31, 2026. This position represents a value of approximately $0.194 million and constitutes a weight of roughly 0.000036% of the total equity, indicating a relatively small but distinct entry into the capital structure. This activity is significant as it contributes to the company's current profile, which includes 25 top holders and one reported officer. With zero analysts currently covering the stock and no index memberships, the emergence of new institutional or significant holders like investor ID 929 may signal early stages of increased visibility or interest in the firm. The detection of this holder change on June 28, 2026, provides a concrete data point for monitoring Enovis Corp's evolving investor landscape. As the company builds its public record, such additions serve as key indicators of how capital is beginning to allocate toward the business amidst its current operational and financial context.

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Enovis Corp (ENOV.K) is a health care equipment and supplies company that operates within the medical device industry. The firm is headquartered in the United States and is primarily listed on the New York Stock Exchange. Specific details regarding its operating segments and geographic revenue mix are not provided in the available data.

    Classification85 %
    SectorHealth Care
    Industry groupHealth Care Equipment & Supplies
    AI synthesis
    GENERATED

    Enovis Corp maintains a capital structure characterized by significant leverage, with long-term debt of $1.26 billion against total equity of $1.49 billion, resulting in a debt-to-equity ratio of 0.85. The company holds only $36.4 million in cash and equivalents, leading to a negative net cash position after subtracting total debt. Liquidity is assessed as medium risk, supported by a current ratio that is not explicitly provided but implied by the balance sheet composition. The market capitalization stands at $1.62 billion, trading at a price-to-book ratio of 1.08, indicating the market values the company close to its tangible book value.

    Profitability metrics are severely negative, with a return on equity of -76.3% and a return on assets of -29.7%. The company reported an operating income of -$1.12 billion and a net income of -$1.18 billion for the latest period, despite generating gross profit of $1.35 billion on revenues of $2.25 billion. This indicates substantial operating expenses or restructuring costs eroding the gross margin. The EV/EBITDA ratio is negative at -2.65, reflecting the current loss-making status. Without cohort median data for direct comparison, these returns suggest the company is in a transitional or distressed phase relative to typical industry peers.

    Revenue concentration details are not provided in the available segments or geography sections. The company’s total revenue is $2.25 billion, but the specific breakdown by product line or region is absent from the input data. Consequently, the degree of exposure to specific markets or customer bases cannot be quantified from the current snapshot.

    Growth trajectory analysis is limited by the absence of historical period data. The latest normalized period shows revenue of $2.25 billion, but without prior year or quarterly comparisons, the direction and velocity of revenue growth cannot be determined. The lack of historical trends prevents an assessment of whether the current revenue base is expanding, contracting, or stable.

    Risk assessment highlights medium liquidity risk and low dilution risk. A key flag notes that net cash is negative after subtracting total debt, which constrains financial flexibility. The low dilution risk suggests that the company is not currently issuing significant new shares, with basic and diluted shares outstanding both at 57.2 million. The negative net cash position remains the primary financial constraint, requiring careful management of operating cash flows.

    Recent observations include analyst estimates with a mean price target of $41.09 and a median of $40.00, implying a potential upside from the current market price of $28.25. The mean recommendation is 1.75, indicating a strong buy consensus among analysts, with 4 strong buys and 7 buys recorded. News events indicate a reconciler enqueue process for analysis jobs, but no specific corporate actions or material news events are disclosed in the observations.

    Enovis Corp (ENOV.K) has recorded a notable addition to its shareholder base, marking the first analysis for this ticker with no prior basis for delta computation. This initial snapshot establishes the baseline for tracking future ownership shifts and market interest in the company. The specific change involves a new holder, identified by investor ID 929, who acquired 200,000 shares as of March 31, 2026. This position represents a value of approximately $0.194 million and constitutes a weight of roughly 0.000036% of the total equity, indicating a relatively small but distinct entry into the capital structure. This activity is significant as it contributes to the company's current profile, which includes 25 top holders and one reported officer. With zero analysts currently covering the stock and no index memberships, the emergence of new institutional or significant holders like investor ID 929 may signal early stages of increased visibility or interest in the firm. The detection of this holder change on June 28, 2026, provides a concrete data point for monitoring Enovis Corp's evolving investor landscape. As the company builds its public record, such additions serve as key indicators of how capital is beginning to allocate toward the business amidst its current operational and financial context.

    Key takeaways
    • Enovis Corp reports significant net losses of $1.18 billion, driven by operating expenses exceeding gross profit of $1.35 billion.
    • The company carries $1.26 billion in long-term debt with only $36.4 million in cash, resulting in a negative net cash position.
    • Analyst sentiment is positive, with a mean recommendation of 1.75 and a mean price target of $41.09, suggesting expected future improvement.
    • Return on equity is -76.3%, indicating severe erosion of shareholder value in the current period.
    • Dilution risk is low, with no difference between basic and diluted shares outstanding.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 5

    Revenue grew 12% annually over four years, reaching $2.25 billion in fiscal 2026, demonstrating consistent top-line expansion.

    Analysts project 45.5% upside to a mean price target of $41.09, reflecting strong institutional confidence in future performance.

    Gross profit increased to $1.31 billion in fiscal 2026, indicating improving operational efficiency and product margin strength.

    The company maintains a current ratio of 2.02, suggesting sufficient short-term liquidity to cover immediate operational obligations.

    Dilution risk is assessed as low, providing reassurance to existing shareholders regarding potential equity value erosion.

    BEAR CASE · 1

    Interest coverage is negative at -32.3x, highlighting an inability to service debt obligations from current operating earnings.

    In focus — financials by report

    Quarterly
    Annual
    QUARTERLYFiled 2026-05-07
    Q1 2026 · Quarter highlights
    Open report →

    Revenue $589.2M, +5,4% YoY; Operating income +114,0% YoY.

    Revenue$589.2M+5,4 % YoY
    Operating income$6.5M+114,0 % YoY
    Net income-$8.8M+84,3 % YoY
    Free cash flow$12.1M+144,3 % YoY
    EPS
    Operating cash flow$24.0M+1 600,7 % YoY
    Financials
    Income statement
    Revenue$589.2M
    Gross profit$365.5M
    Operating income$6.5M
    Net income-$8.8M
    Margins
    Gross margin62.0%
    Operating margin1.1%
    Net margin-1.5%
    FCF margin2.1%
    Balance sheet
    Total assets$3.83B
    Total liabilities$2.36B
    Total equity$1.48B
    Cash & equivalents$33.1M
    Long-term debt$1.33B
    Cash flow
    Operating cash flow$24.0M
    CapEx-$52.8M
    Free cash flow$12.1M
    SBC
    P&L flow · revenue → net income
    Revenue $589.2MOperating costs $582.6MTax $15.3MNet income $8.8M
    Highlights
    • Revenue $589.2M, +5,4% YoY
    • Operating income +114,0% YoY
    • Net income +84,3% YoY
    • Free cash flow +144,3% YoY
    • Net margin -1.5%

    Valuation TTM

    Market price
    $28,25
    Market cap
    $1.62B
    Enterprise value
    $2.84B
    P/E
    Non-GAAP P/E
    EV / Revenue
    1.2x
    EV / Op income
    EV / OCF
    13.1x
    P / B
    1.1x
    P / Tangible book
    1.1x
    Tangible book
    $1.49B
    Net cash
    -$1.23B
    Current ratio
    Debt / equity
    0.8
    ROA
    -29.7%
    ROE
    -76.3%
    Cash conversion
    -19.0%
    CapEx / revenue
    -8.7%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    Business relationships86 disclosed relationships · 1 type · extracted from filings & disclosures
    Subsidiaries86
    EX21:0537e3b7cbccEX21:0537e3b7cbccSubsidiarie97%
    EX21:07d414029233EX21:07d414029233Subsidiarie97%
    EX21:08b00e56bd3aEX21:08b00e56bd3aSubsidiarie97%
    EX21:0bfc1a4d38a3EX21:0bfc1a4d38a3Subsidiarie97%
    EX21:11a1b0e58657EX21:11a1b0e58657Subsidiarie97%
    EX21:11bd02fec254EX21:11bd02fec254Subsidiarie97%
    EX21:147748e8ab52EX21:147748e8ab52Subsidiarie97%
    EX21:1b90b855e7cfEX21:1b90b855e7cfSubsidiarie97%
    EX21:22560c233a30EX21:22560c233a30Subsidiarie97%
    EX21:2aa0d289cdbaEX21:2aa0d289cdbaSubsidiarie97%
    EX21:3d3ad049a48fEX21:3d3ad049a48fSubsidiarie97%
    EX21:3e3b3faea514EX21:3e3b3faea514Subsidiarie97%
    EX21:43e1d119b196EX21:43e1d119b196Subsidiarie97%
    EX21:458d70ed47e5EX21:458d70ed47e5Subsidiarie97%
    EX21:475e03023abcEX21:475e03023abcSubsidiarie97%
    EX21:4c51267ec2d2EX21:4c51267ec2d2Subsidiarie97%
    EX21:541d38768431EX21:541d38768431Subsidiarie97%
    EX21:55cf772b601aEX21:55cf772b601aSubsidiarie97%
    EX21:563a9492e1bcEX21:563a9492e1bcSubsidiarie97%
    EX21:5b47647529ddEX21:5b47647529ddSubsidiarie97%
    EX21:5c1c2246a86cEX21:5c1c2246a86cSubsidiarie97%
    EX21:606de728f69bEX21:606de728f69bSubsidiarie97%
    EX21:60bd6aff33aeEX21:60bd6aff33aeSubsidiarie97%
    EX21:62cf5a36d2deEX21:62cf5a36d2deSubsidiarie97%
    EX21:67d4143062b5EX21:67d4143062b5Subsidiarie97%
    EX21:68854d5702b9EX21:68854d5702b9Subsidiarie97%
    EX21:68eb39b35ac1EX21:68eb39b35ac1Subsidiarie97%
    EX21:69738eb800eeEX21:69738eb800eeSubsidiarie97%
    EX21:6b2ddab0a106EX21:6b2ddab0a106Subsidiarie97%
    EX21:6b47eb687984EX21:6b47eb687984Subsidiarie97%
    EX21:6ba4e2a8445dEX21:6ba4e2a8445dSubsidiarie97%
    EX21:700bd3608a54EX21:700bd3608a54Subsidiarie97%
    EX21:765fc89f32efEX21:765fc89f32efSubsidiarie97%
    EX21:77b3b8de5854EX21:77b3b8de5854Subsidiarie97%
    EX21:78e8b4d65f76EX21:78e8b4d65f76Subsidiarie97%
    EX21:7e2f036527deEX21:7e2f036527deSubsidiarie97%
    EX21:80c67987d100EX21:80c67987d100Subsidiarie97%
    EX21:82a200de4820EX21:82a200de4820Subsidiarie97%
    EX21:86e3db78c34bEX21:86e3db78c34bSubsidiarie97%
    EX21:8815077aa8f4EX21:8815077aa8f4Subsidiarie97%
    EX21:92d219b5b19dEX21:92d219b5b19dSubsidiarie97%
    EX21:9448f2bad7e5EX21:9448f2bad7e5Subsidiarie97%
    EX21:959bf25969afEX21:959bf25969afSubsidiarie97%
    EX21:966b817def4bEX21:966b817def4bSubsidiarie97%
    EX21:991bb71afc37EX21:991bb71afc37Subsidiarie97%
    EX21:9b2b12e14115EX21:9b2b12e14115Subsidiarie97%
    EX21:9f458f38e0d5EX21:9f458f38e0d5Subsidiarie97%
    EX21:a2bf18c7d5a2EX21:a2bf18c7d5a2Subsidiarie97%
    EX21:a69f837d295aEX21:a69f837d295aSubsidiarie97%
    EX21:b0290e67e87aEX21:b0290e67e87aSubsidiarie97%
    EX21:b180d28d7ea7EX21:b180d28d7ea7Subsidiarie97%
    EX21:b2537467ac81EX21:b2537467ac81Subsidiarie97%
    EX21:b32d4a189c73EX21:b32d4a189c73Subsidiarie97%
    EX21:b35ab60a9ad6EX21:b35ab60a9ad6Subsidiarie97%
    EX21:b39583149d97EX21:b39583149d97Subsidiarie97%
    EX21:b45e830aeab0EX21:b45e830aeab0Subsidiarie97%
    EX21:b6be26a46b3aEX21:b6be26a46b3aSubsidiarie97%
    EX21:baee4c42f9edEX21:baee4c42f9edSubsidiarie97%
    EX21:be7dc02c9d66EX21:be7dc02c9d66Subsidiarie97%
    EX21:bed56b686657EX21:bed56b686657Subsidiarie97%
    EX21:bed9085c7b03EX21:bed9085c7b03Subsidiarie97%
    EX21:bef854fcb304EX21:bef854fcb304Subsidiarie97%
    EX21:c03e7a8f16c5EX21:c03e7a8f16c5Subsidiarie97%
    EX21:c9144f12b6ecEX21:c9144f12b6ecSubsidiarie97%
    EX21:cc512c8ac526EX21:cc512c8ac526Subsidiarie97%
    EX21:cd8355c32793EX21:cd8355c32793Subsidiarie97%
    EX21:d504feec549eEX21:d504feec549eSubsidiarie97%
    EX21:d8503a10d129EX21:d8503a10d129Subsidiarie97%
    EX21:dac9ae2b525aEX21:dac9ae2b525aSubsidiarie97%
    EX21:ddc379e3884bEX21:ddc379e3884bSubsidiarie97%
    EX21:e010a8345f2dEX21:e010a8345f2dSubsidiarie97%
    EX21:e17a72aa1e23EX21:e17a72aa1e23Subsidiarie97%
    EX21:e5b48af0aab1EX21:e5b48af0aab1Subsidiarie97%
    EX21:e5f6752c3d11EX21:e5f6752c3d11Subsidiarie97%
    EX21:e997e0f18c11EX21:e997e0f18c11Subsidiarie97%
    EX21:eb5a0aa5c059EX21:eb5a0aa5c059Subsidiarie97%
    EX21:ecdc8377b73cEX21:ecdc8377b73cSubsidiarie97%
    EX21:ef5af2280871EX21:ef5af2280871Subsidiarie97%
    EX21:efbe03694316EX21:efbe03694316Subsidiarie97%
    EX21:f00d0d985733EX21:f00d0d985733Subsidiarie97%
    EX21:f161072419cbEX21:f161072419cbSubsidiarie97%
    EX21:f44aaa73c728EX21:f44aaa73c728Subsidiarie97%
    EX21:f68037abc082EX21:f68037abc082Subsidiarie97%
    EX21:f8e36ec73a2dEX21:f8e36ec73a2dSubsidiarie97%
    EX21:fc4d0ebbf004EX21:fc4d0ebbf004Subsidiarie97%
    EX21:fffdbd715a2aEX21:fffdbd715a2aSubsidiarie97%

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    3,65
    Predicted surprise
    0,00
    Beat probability
    45 %
    Analysts
    12
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-07-28 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate3,65
    Revenueno estimateno estimate2,3B USD
    Operating incomeno estimateno estimate284,1M USD
    Full-year consensus mean (period as reported by source) · consensus in USD. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Corporate eventM&A horizon
    M&A probabilityconf 5 %
    Probability
    5 %
    Base rate
    3 %
    Band
    180-day horizon · target 2027-01-23 · 1,8× base rate
    No acquirer candidates identified by the signal model.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution12 analysts
    Strong buy4
    Buy7
    Hold1
    Sell0
    Strong sell0
    12-month price target$41,09 · Median $40,00
    Low $29,00High $55,00
    Operating income · consensus284,1M USD
    EPS surprise
    −9,5 %
    reported vs consensus · miss
    Revenue surprise
    −4,1 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$29,00
    Mean$41,09
    Median$40,00
    High$55,00
    Spot$28,25
    +45.5 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-47,1 %Bottom quartile
    Net Margin-49,9 %Bottom quartile
    ROE-76,3 %Bottom quartile
    Capex / Rev-8,7 %Bottom quartile
    D/E0,85Bottom quartile
    Cash Conv-0,19Below median

    Corporate actions / M&A

    M&A probabilityconf —
    Probability
    5 %
    Base rate
    3 %
    Band
    Moderate
    180-day horizon · target 2027-01-23 · 1,8× base rate
    No acquirer candidates identified by the signal model.
    Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Reference data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Price To Tangible Book
      market_price / (tangible_book_value / shares_outstanding_diluted)
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Return On Equity
      net_income / total_equity
    • Enterprise Value
      market_cap - net_cash
    • Ev To Revenue
      enterprise_value / revenue
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    Source documents
    • Enovis CORP Market data — financials · 2026-07-28
    • reconciler_enqueue (reconciler) on ENOV.K · 2026-07-28
    • Enovis Corp Market data — analyst estimates · 2026-07-28
    • Enovis Corp Market data — ESG · 2026-07-28
    • Enovis Corp HA canonical relationships · 2026-07-28

    Ownership & reference

    Top holders

    • American Century Investment Management, Inc.Investment Managers · as of 2026-03-310,06 %$108M
    • Dimensional Fund Advisors, L.P.Investment Managers · as of 2026-03-310,01 %$58M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,01 %$245M
    • Goldman Sachs Asset Management, L.P.Investment Managers · as of 2026-03-310,00 %$36M
    • JANUS HENDERSON GROUP PLCInstitutional Investor · as of 2026-03-310,00 %$9M
    • Charles Schwab Investment Management, Inc.Investment Managers · as of 2026-03-310,00 %$23M
    • Principal Global Investors (Equity)Investment Managers · as of 2026-03-310,00 %$6M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$19M
    • AQR Capital Management, LLCInvestment Managers · as of 2026-03-310,00 %$6M
    • Nuveen LLCInvestment Managers · as of 2024-12-310,00 %$10M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$172M
    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$31M
    • Northern Trust Investments, Inc.Investment Managers · as of 2026-03-310,00 %$14M
    • FMR LLCInstitutional Investor · as of 2026-03-310,00 %$31M
    • Raymond James & Associates, Inc.Brokerage Firms · as of 2026-03-310,00 %$5M
    • Invesco QQQ TrustFunds · as of 2026-03-310,00 %$5M
    • AllianceBernstein L.P.Investment Managers · as of 2026-03-310,00 %$2M
    • AMERIPRISE FINANCIAL INCInstitutional Investor · as of 2026-03-310,00 %$2M
    • LPL Financial LLCInvestment Managers · as of 2026-03-310,00 %$2M
    • JONES FINANCIAL COMPANIES LLLPInstitutional Investor · as of 2026-03-310,00 %$0M
    • T. Rowe Price Associates, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • PNC Investments LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • Victory Capital Management Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Franklin Advisers, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Bank of New York Mellon CorpInstitutional Investor · as of 2026-03-310,00 %$0M

    Leadership

    • Matthew L. TrerotolaChairman of the Board, Chief Executive Officer

    Insider activity

    Net buying7 buys · 0 sellsnet $140K17 insiders · last 365d
    • Ortiz ChristineDirector · Common stock, par value $0.001Other 846 · 2026-06-30
    • Engert OliverChief Administrative Officer · Common stock, par value $0.001Bought 1 000 @ $20,92$21K · 2026-06-15
    • Engert OliverChief Administrative Officer · Common stock, par value $0.001Bought 1 000 @ $21,75$22K · 2026-06-11
    • Engert OliverChief Administrative Officer · Common stock, par value $0.001Bought 200 @ $20,99$4K · 2026-06-11
    • Engert OliverChief Administrative Officer · Common stock, par value $0.001Bought 1 000 @ $23,00$23K · 2026-06-10
    • Engert OliverChief Administrative Officer · Common stock, par value $0.001Bought 1 000 @ $22,22$22K · 2026-06-01
    • Wienbar Sharon LDirector · Common stock, par value $0.001Other 9 346 · 2026-05-19
    • Shirley BradyDirector · Common stock, par value $0.001Other 9 346 · 2026-05-19
    • Bodem Barbara W.Director · Common stock, par value $0.001Other 9 346 · 2026-05-19
    • Okala PhilipDirector · Common stock, par value $0.001Other 9 346 · 2026-05-19
    • Ortiz ChristineDirector · Common stock, par value $0.001Other 9 346 · 2026-05-19
    • Lalor Angela SDirector · Common stock, par value $0.001Other 9 346 · 2026-05-19
    • PERFALL A CLAYTONDirector · Common stock, par value $0.001Other 9 346 · 2026-05-19
    • Kelly LiamDirector · Common stock, par value $0.001Other 9 346 · 2026-05-19
    • Vinnakota RajivDirector · Common stock, par value $0.001Other 9 346 · 2026-05-19
    • McDonald DamienDirector, Chief Executive Officer · Common stock, par value $0.001Other 12 634 @ $25,99$328K · 2026-05-12
    • BERRY PHILLIP BENJAMIN (BEN)SVP, Chief Financial Officer · Common stock, par value $0.001Other 7 774 @ $25,99$202K · 2026-05-12
    • Ortiz ChristineDirector · Common stock, par value $0.001Other 770 · 2026-03-31
    • Engert OliverChief Administrative Officer · Common stock, par value $0.001Bought 1 000 @ $23,74$24K · 2026-03-13
    • Engert OliverChief Administrative Officer · Common stock, par value $0.001Bought 1 000 @ $23,93$24K · 2026-03-10
    • Lang Patricia ASVP, Chief HR Officer · Common stock, par value $0.001Other 25 586 · 2026-03-09
    • VOGT LOUISGROUP PRESIDENT, RECON · Common stock, par value $0.001Other 36 247 · 2026-03-09
    • KLECKNER JOHNPrincipal Accounting Officer · Common stock, par value $0.001Other 14 925 · 2026-03-09
    • Tandy Bradley JSVP and Chief Legal Officer · Common stock, par value $0.001Other 25 586 · 2026-03-09
    • ROSS TERRY DGROUP PRESIDENT, P&R · Common stock, par value $0.001Other 36 247 · 2026-03-09

    Short positioning

    8.3Mshares short-12.1% vs prior
    6.6days to cover
    49.5%short of daily vol
    3fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    ENOV.KCanonical
    NYSE · USD

    Intel & risk

    PredictorBeat prob45 %Surprise0,00M&A prob5 %Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.
    Relationship graph
    ENOVEX21:053EX21:07dEX21:08bEX21:0bfEX21:11aEX21:11bEX21:147EX21:1b9EX21:225EX21:2aaHealth Care Eq
    This companySectorSubsidiaries

    Evidence & claims

    From filings & derived data
    • Cash & equivalents (annual): USD 36.39MUnknown
    • Shares outstanding (annual): 57.19MUnknown
    • EPS (diluted) (annual): USD-PER-SHARES -21Unknown
    • Gross profit (annual): USD 1.35BUnknown
    • Pre-tax income (annual): USD -1.16BUnknown
    • Capex (annual): USD 197.38MUnknown
    • Shareholders' equity (annual): USD 1.49BUnknown
    • Total liabilities (annual): USD 2.34BUnknown
    • Operating income (annual): USD -1.12BUnknown
    • Current assets (annual): USD 1.21BUnknown
    • Current liabilities (annual): USD 598.47MUnknown
    • EPS (basic) (annual): USD-PER-SHARES -21Unknown
    • Interest expense (annual): USD 34.82MUnknown
    • Operating cash flow (annual): USD 217.29MUnknown
    • R&D expense (annual): USD 120.33MUnknown
    • Revenue (annual): USD 2.25BUnknown
    • Cost of revenue (annual): USD 902.79MUnknown
    • Net income (annual): USD -1.18BUnknown
    • Total assets (annual): USD 3.83BUnknown
    • Long-term debt (annual): USD 1.3BUnknown
    • Current assets (annual): USD 1.15BUnknown
    • EPS (diluted) (annual): USD-PER-SHARES -15Unknown
    • Current liabilities (annual): USD 529MUnknown
    • Operating cash flow (annual): USD 113.5MUnknown
    Showing 24 of 40 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)
    2026-06-30INSIDEROrtiz Christine transacted 846 sh Common stock, par value $0.001 — Director
    2026-06-28 03:14 UTCHOLDERInstitutional holding changed
    2026-06-28 03:14 UTCHOLDER1 institutional position change flagged
    2026-06-15 00:00 UTCINSIDER5 insider transactions — 2026-06
    2026-06-15 00:00 UTCINSIDER5 insider transactions — 2026-06
    2026-06-15INSIDEREngert Oliver bought 1.0k sh Common stock, par value $0.001 — Chief Administrative Officer ~$21k
    2026-06-11INSIDEREngert Oliver bought 1.0k sh Common stock, par value $0.001 — Chief Administrative Officer ~$22k
    2026-06-11INSIDEREngert Oliver bought 200 sh Common stock, par value $0.001 — Chief Administrative Officer ~$4k
    2026-06-10INSIDEREngert Oliver bought 1.0k sh Common stock, par value $0.001 — Chief Administrative Officer ~$23k
    2026-06-01INSIDEREngert Oliver bought 1.0k sh Common stock, par value $0.001 — Chief Administrative Officer ~$22k
    2026-05-19 00:00 UTCINSIDER11 insider transactions — 2026-05 · net sell $530k
    2026-05-19 00:00 UTCINSIDER11 insider transactions — 2026-05 · net sell $530k
    2026-05-19FILING8-K filing →
    2026-05-19INSIDERWienbar Sharon L transacted 9.3k sh Common stock, par value $0.001 — Director
    2026-05-19INSIDERShirley Brady transacted 9.3k sh Common stock, par value $0.001 — Director
    2026-05-19INSIDERBodem Barbara W. transacted 9.3k sh Common stock, par value $0.001 — Director
    2026-05-19INSIDEROkala Philip transacted 9.3k sh Common stock, par value $0.001 — Director
    2026-05-19INSIDEROrtiz Christine transacted 9.3k sh Common stock, par value $0.001 — Director
    2026-05-19INSIDERLalor Angela S transacted 9.3k sh Common stock, par value $0.001 — Director
    2026-05-19INSIDERPERFALL A CLAYTON transacted 9.3k sh Common stock, par value $0.001 — Director
    2026-05-19INSIDERKelly Liam transacted 9.3k sh Common stock, par value $0.001 — Director
    2026-05-19INSIDERVinnakota Rajiv transacted 9.3k sh Common stock, par value $0.001 — Director
    2026-05-12INSIDERMcDonald Damien transacted 12.6k sh Common stock, par value $0.001 — Director, Chief Executive Officer ~$328k
    2026-05-12INSIDERBERRY PHILLIP BENJAMIN (BEN) transacted 7.8k sh Common stock, par value $0.001 — SVP, Chief Financial Officer ~$202k
    2026-05-07 06:12 UTCEARNINGSQuarterly results — Q1 2026 Revenue USD 589.2M · Net USD -8.8M
    2026-05-07FILING10-Q filing →
    2026-05-07FILING8-K filing →
    2026-04-06FILINGDEF 14A filing →
    2026-03-31 00:00 UTCINSIDER15 insider transactions — 2026-03 · net sell $270k
    2026-03-31 00:00 UTCINSIDER15 insider transactions — 2026-03 · net sell $270k
    2026-03-31INSIDEROrtiz Christine transacted 770 sh Common stock, par value $0.001 — Director
    2026-03-13INSIDEREngert Oliver bought 1.0k sh Common stock, par value $0.001 — Chief Administrative Officer ~$24k
    2026-03-10INSIDEREngert Oliver bought 1.0k sh Common stock, par value $0.001 — Chief Administrative Officer ~$24k
    2026-03-09INSIDERLang Patricia A transacted 25.6k sh Common stock, par value $0.001 — SVP, Chief HR Officer
    2026-03-09INSIDERVOGT LOUIS transacted 36.2k sh Common stock, par value $0.001 — GROUP PRESIDENT, RECON
    2026-03-09INSIDERKLECKNER JOHN transacted 14.9k sh Common stock, par value $0.001 — Principal Accounting Officer
    2026-03-09INSIDERTandy Bradley J transacted 25.6k sh Common stock, par value $0.001 — SVP and Chief Legal Officer
    2026-03-09INSIDERROSS TERRY D transacted 36.2k sh Common stock, par value $0.001 — GROUP PRESIDENT, P&R
    Showing the 40 most recent of 60 entries.
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Reference data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage